Cosmo Bio Co

Cosmo Bio Co Liabilities

The The Liabilities of Cosmo Bio Co (3386.T) as of Oct 27, 2026 is 2.70 B JPY. In the previous year, The Liabilities was 2.17 B JPY — a change of 24.84% (higher).

Liabilities

2.70 BJPY

YoY

24.84%

Last updated:

In 2025, Cosmo Bio Co's total liabilities amounted to 2.70 B JPY, a 24.84% difference from the 2.17 B JPY total liabilities in the previous year.

The Cosmo Bio Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.45 B JPY
Jan 1, 2019
1.57 B JPY
Jan 1, 2020
1.78 B JPY
Jan 1, 2021
1.75 B JPY
Jan 1, 2022
1.69 B JPY
Jan 1, 2023
1.84 B JPY
Jan 1, 2024
2.17 B JPY
Jan 1, 2025
2.70 B JPY
The Cosmo Bio Co Liabilities history
YEARLiabilitiesYoY
2.70 BJPY+24.84%
2.17 BJPY+17.46%
1.84 BJPY+8.92%
1.69 BJPY-3.26%
1.75 BJPY-1.46%
1.78 BJPY+13.41%
1.57 BJPY+8.37%
1.45 BJPY+12.36%
1.29 BJPY-4.74%
1.35 BJPY-4.39%
1.41 BJPY-13.32%
1.63 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Cosmo Bio Co's Liabilities

Cosmo Bio Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cosmo Bio Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cosmo Bio Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cosmo Bio Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cosmo Bio Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cosmo Bio Co stock

The Liabilities of Cosmo Bio Co is 2.70 B JPY in 2025.

The Liabilities of Cosmo Bio Co changed from 2.17 B JPY to 2.70 B JPY, representing a 24.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co